|
Sensory Neuropathy, Hereditary
|
0.220 |
Biomarker
|
disease |
BEFREE |
Biochemical characterization of mutants in chaperonin proteins CCT4 and CCT5 associated with hereditary sensory neuropathy.
|
25124038 |
2014 |
|
Sensory Neuropathy, Hereditary
|
0.220 |
Biomarker
|
disease |
RGD |
Hereditary sensory neuropathy is caused by a mutation in the delta subunit of the cytosolic chaperonin-containing t-complex peptide-1 (Cct4 ) gene.
|
12874111 |
2003 |
|
Sensory Neuropathy, Hereditary
|
0.220 |
GeneticVariation
|
disease |
BEFREE |
Hereditary sensory neuropathy is caused by a mutation in the delta subunit of the cytosolic chaperonin-containing t-complex peptide-1 (Cct4 ) gene.
|
12874111 |
2003 |
|
Amino acids measurement
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genetic basis for plasma amino acid concentrations based on absolute quantification: a genome-wide association study in the Japanese population.
|
30659259 |
2019 |
|
Methionine measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic basis for plasma amino acid concentrations based on absolute quantification: a genome-wide association study in the Japanese population.
|
30659259 |
2019 |
|
Threonine measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic basis for plasma amino acid concentrations based on absolute quantification: a genome-wide association study in the Japanese population.
|
30659259 |
2019 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The synthesized pyrimidine scaffolds were screened for their antimicrobial activity by tube dilution method as well for antiproliferative activity (human colorectal (HCT116) cancer cell line) by SRB assay.
|
30306864 |
2019 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The synthesized compounds were examined for their cytotoxic effects using SRB assay on three cancer cell lines HepG2, HCT116 and MCF-7.
|
31288134 |
2019 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Additionally, <i>in vitro</i> anticancer activity of the complexes were evaluated by SRB assay on selected cancer cell lines viz., HeLa (cervical), MIA-PA-CA-2 (pancreatic), MCF-7 (breast), Hep-G2 (Hepatoma), and SK-OV-3 (ovarian) which exhibited the superior cytotoxicity of complex [C<sub>31</sub>H<sub>35</sub>O<sub>4</sub>SeRuCl] as compared to other analogs on selective cancer phenotypes.Communicated by Ramaswamy H. Sarma.
|
30124119 |
2019 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Substrates efflux assay and P-gp ATPase activity assay were conducted to reveal the molecular mechanisms of P-gp inhibition, while SRB assay, cell cycle analyses and apoptosis analyses were performed to confirm the cancer MDR modulating effects.
|
31766413 |
2019 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Substrates efflux assay and P-gp ATPase activity assay were conducted to reveal the molecular mechanisms of P-gp inhibition, while SRB assay, cell cycle analyses and apoptosis analyses were performed to confirm the cancer MDR modulating effects.
|
31766413 |
2019 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Additionally, <i>in vitro</i> anticancer activity of the complexes were evaluated by SRB assay on selected cancer cell lines viz., HeLa (cervical), MIA-PA-CA-2 (pancreatic), MCF-7 (breast), Hep-G2 (Hepatoma), and SK-OV-3 (ovarian) which exhibited the superior cytotoxicity of complex [C<sub>31</sub>H<sub>35</sub>O<sub>4</sub>SeRuCl] as compared to other analogs on selective cancer phenotypes.Communicated by Ramaswamy H. Sarma.
|
30124119 |
2019 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
The synthesized pyrimidine scaffolds were screened for their antimicrobial activity by tube dilution method as well for antiproliferative activity (human colorectal (HCT116) cancer cell line) by SRB assay.
|
30306864 |
2019 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
The synthesized compounds were examined for their cytotoxic effects using SRB assay on three cancer cell lines HepG2, HCT116 and MCF-7.
|
31288134 |
2019 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Cancer cell sensitivity to chemotherapy was detected by SRB assay.
|
29921847 |
2018 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
They were examined for their cytotoxic effects using SRB assay on four cancer cell lines HepG2, HCT116, CACO and MCF-7 in addition to the non-cancerous human cell line.
|
30096580 |
2018 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Antitumor activity for the prepared compounds against human breast adenocarcinoma (MCF-7), liver (HEPG2) and colon (HCT116) cancer cell lines was evaluated using SRB assay method.
|
29629667 |
2018 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Antitumor activity for the prepared compounds against human breast adenocarcinoma (MCF-7), liver (HEPG2) and colon (HCT116) cancer cell lines was evaluated using SRB assay method.
|
29629667 |
2018 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Cancer cell sensitivity to chemotherapy was detected by SRB assay.
|
29921847 |
2018 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
They were examined for their cytotoxic effects using SRB assay on four cancer cell lines HepG2, HCT116, CACO and MCF-7 in addition to the non-cancerous human cell line.
|
30096580 |
2018 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The biological activities of these molecules have been evaluated against various human cancer cell lines A549 (Lung adenocarcinoma cell line), MCF-7 (Breast carcinoma cell line), HCT-116 (Colon cancer cell line), and PC-3 (Prostate cancer cell line) through SRB assay.
|
27889631 |
2017 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Based on our previous work, the cytotoxicity of these derivatives were evaluated by the SRB method against 293T cell lines and three cancer cell lines: A549, Hela and MCF-7.
|
28237792 |
2017 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Based on our previous work, the cytotoxicity of these derivatives were evaluated by the SRB method against 293T cell lines and three cancer cell lines: A549, Hela and MCF-7.
|
28237792 |
2017 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
The biological activities of these molecules have been evaluated against various human cancer cell lines A549 (Lung adenocarcinoma cell line), MCF-7 (Breast carcinoma cell line), HCT-116 (Colon cancer cell line), and PC-3 (Prostate cancer cell line) through SRB assay.
|
27889631 |
2017 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The cytotoxic potential of complex 1 was analyzed by SRB assay on a panel of selected human cancer cell lines which revealed selective activity for MCF-7 (breast cancer) cell line with GI<sub>50</sub> = 16.21 µg/ml.
|
31735357 |
2020 |